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a  b  s  t  r  a  c  t
Dengue  vaccine  development  efforts  have  focused  on  the  development  of  tetravalent  vaccines.  However,
a  recent  Phase  IIb  trial  of  a  tetravalent  vaccine  indicates  a  protective  effect  against  only  3  of the 4  serotypes.
While  vaccines  effective  against  a subset  of  serotypes  may  reduce  morbidity  and  mortality,  particular
proﬁles  could  result  in  an  increased  number  of  cases  due  to  immune  enhancement  and  other  peculiarities




partially  effective  vaccines  in  a  hyperendemic  Thai  population.  Crucially,  we  evaluate  the  effects  that
certain serotype  heterogeneities  may  have  in  the  presence  of  mass-vaccination  campaigns.
In the  majority  of scenarios  explored,  partially  effective  vaccines  lead  to 50%  or greater  reductions  in
the  number  of cases.  This  is  true  even  of vaccines  that  we would  not  expect  to  proceed  to licensure  due
to  poor  or  incomplete  immune  responses.  Our  results  show  that  a partially  effective  vaccine  can  have
signiﬁcant  impacts  on  serotype  distribution  and  mean  age  of  cases.
 201©
. Introduction
Due to the possibility of severe disease arising from vaccine-
nduced immunity, the ideal dengue vaccine is one that has high
nd equal efﬁcacy against all four serotypes. However, this ideal
ay  be difﬁcult to attain. The results of a recent Phase IIb trial
ndicate that the vaccine candidate furthest along in development
rotects against serotypes 1, 3 and 4 but not serotype 2 [1]. Though
everal statements of vaccine requirements have said that vaccines
ust protect against all four serotypes, partially effective vaccines
ay  reduce morbidity and mortality [2,3]. Conversely, speciﬁc par-
ially effective vaccines may  result in increased clinical disease due
o inducing immunity that pre-disposes individuals to more severe
isease [4]. The potential population-level impacts of a partially
ffective vaccine have not been explored [5].
The dengue viruses exist as four antigenically distinct serotypes.
nfection with one strain is thought to induce a life-long pro-
ective immune response to other viruses of the same serotype
homotypic immunity) and a short-term cross-protective response
gainst other serotypes (heterotypic immunity), but waning
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heterotypic immunity has been associated with more severe ill-
ness upon secondary infection [6,7]. After secondary infection
individuals generate a strong serological response that is broadly
cross-reactive and, despite some evidence of tertiary and quater-
nary infections, it is generally assumed that most individuals can
only undergo up to two infections [8].
While the target of dengue vaccine design has been to generate a
balanced protective serological response to all four serotypes, vac-
cines targeting other antigenically diverse pathogens have shown
a substantial public health impact even when inducing immunity
to a subset of types of pathogen. Examples include pneumococcal
conjugate vaccines [9], Human Papillomavirus (HPV) [10,11] and
Haemophilus inﬂuenza B vaccines [12,13]. While dengue is unique
due to the association that exists between secondary exposure and
more severe forms of the disease, it is not clear that this difference
needs to fundamentally change our approach to controlling dengue
compared to other pathogens.
Evaluation of the potential impact of partially effective vaccines
through simulation requires consideration of scenarios with het-
erogeneities between serotypes like those that are likely to exist
in endemic/hyperendemic settings. Estimates of the force of infec-
tion derived from age-stratiﬁed seroprevalence studies conducted
in Rayong, Thailand in 1980/1981 and 2010 suggest that the aver-
Open access under CC BY-NC-ND license.age transmission intensity (and R0) of DENV-2 is higher than that of
other serotypes [14,15]. Heterogeneity in the propensity to develop
severe disease following infection with different serotypes has also
been documented in multiple studies in Thailand and Nicaragua
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16–19]. While the extent of immune enhancement of susceptibil-
ty/infectiousness by different infection sequences has been more
ifﬁcult to estimate, there is some evidence to suggest that it might
lso vary between serotypes [14]. Furthermore, recent work sug-
ests that such immune enhancement is important for serotype
ersistence in the presence of transmission heterogeneity [20].
The potential impact of vaccination on dengue transmission
ynamics in Thailand and Vietnam has been explored in two
ecent publications by Chao et al. [21] and Coudeville et al. [22]
sing an agent-based model and an age-speciﬁc compartmen-
al model, respectively. Both of these studies found that vaccines
ith efﬁcacy of 70–90% against all serotypes have the potential
o signiﬁcantly reduce the frequency and magnitude of epi-
emics on a short to medium term. However, while both of these
odels do account for some sources of heterogeneity between
erotypes, for example, differences between the serotypes in trans-
ission intensity, they do not systematically examine the potential
mpact of these heterogeneities in the context of partially effective
accines.
Here, we use an age-stratiﬁed dengue transmission model to
ssess the potential impact of vaccines with high efﬁcacy against
engue serotypes 1, 3 and 4 and low efﬁcacy against dengue
erotype 2 in a hyperendemic Thai population. We  explore mul-
iple disease/transmission scenarios to identify those that might
ead to increases in clinically apparent cases and to identify the
otential reductions in disease. Crucially, we evaluate the effects
hat certain serotype heterogeneities may  have in the presence of
ass-vaccination campaigns. We  also explore overall, direct and
ndirect effects of reducing (or in some cases increasing) infection
nd disease in vaccinated individuals vs. reductions in transmission
opulation wide.
. Materials and methods
.1. Mathematical model
We  formulated a deterministic, age-stratiﬁed compartmental
engue transmission model that includes explicit vector dynam-
cs as well as cross-protection and infectiousness enhancement
etween dengue serotypes. Humans are assumed to be born sus-
eptible and can undergo up to two infections by heterologous
erotypes. Mosquito vectors are classiﬁed as susceptible or infected
y each of the circulating serotypes.
We  focus on the dengue vaccine being developed by Sanoﬁ-
asteur that requires three doses to achieve high protection.
accination reduces the susceptibility of vaccinated humans to
engue infection. We  also allow for immune mediated vaccine
nduced enhancement in transmissibility.
Since the main objective of our study was to explore changes
n the number of clinically apparent dengue cases, upon mass-
accination, we made assumptions about the probability of
eveloping clinically apparent disease following infection. These
ssumptions also allowed us to calibrate our model with data from
urveillance systems. We  assumed that: (i) in unvaccinated indi-
iduals, clinical cases arise mostly from secondary infections; (ii)
n vaccinated individuals, clinical cases arise majorly from primary
nfection, but can arise from secondary infections depending on
he vaccine’s efﬁcacy against heterologous serotypes. Although we
onservatively assumed the probability of clinical infection to be
ndependent of age, we performed sensitivity analyses to consider
ge dependence as has been previously considered.
We discuss our mathematical model and related assumptions in
ore detail in the supplementary material (Supplementary mate-
ial S1).Fig. 1. Output from the model compared to (A) age-speciﬁc incidence from Rayong
reported to the Ministry of Public Health, Thailand, 2002–2008. (B) Results from an
age-stratiﬁed serological study conducted in Rayong district, 2010.
2.2. Vaccination campaign parameters
For all simulations, we assumed that that the vaccine was
equally effective against serotypes DENV-1, DENV-3 and DENV-4
(vaccine efﬁcacy = 0.8, after 3 doses) but only partially effective
against DENV-2. We  also assumed that vaccine-derived immu-
nity does not wane. Rollout of the vaccine consisted of 3 years of
catch-up targeting children 2–15 years of age, followed by regular
vaccination of 2–5 year olds. The vaccine was  administered in up
to three doses that were given on average every six months apart.
Vaccination rates in catch-up and routine programs were constant
over time and set so that vaccination coverage would reach 89%
among 2–5 year olds and 69% in 2–15 year olds after 5 years. These
vaccination rates were chosen to roughly correspond with the rate
of vaccination achieved in Thailand with the Japanese Encephalitis
three-dose vaccination using a combination of catch-up and routine
immunization campaigns.
2.3. Vaccine effects
To explore the effects of vaccination at the population level, we
compared the cumulative number of clinically apparent dengue
cases in the 10 years after vaccine introduction, to the cumulative
number of cases over the same period in the counterfactual popula-
tion (i.e. same population had the vaccine not been introduced).
We  also isolated overall,  direct and indirect vaccine effects as pro-
posed by Halloran et al. [23]. In addition, we deﬁned a counterfactual
vaccine effect, comparing the cumulative incidence in vaccinated
individuals of the vaccinated population to the cumulative inci-
dence in “vaccinated” individuals of the counterfactual population
(Supplementary material S1).
Since timing of vaccine introduction may impact the short and
medium term effects of vaccination, we performed simulations
introducing the vaccine at different points in the multiannual
dengue cycle. We  present vaccine effects that are averages over
eight possible introduction years.
3. Results
3.1. Calibration and ﬁt
We  calibrated the model, at steady state, to the transmission
dynamics of dengue in Rayong, Thailand, a traditionally hyper-
endemic setting (Fig. 1). To ﬁt the model to the demography of
Rayong, we used data from the 2010 Thai Census [24] (Supple-
mentary Fig. S2.1). To estimate transmission parameters, we used
age-speciﬁc incidence data from the Ministry of Public of Pub-
lic Health (2002–2010) and age-stratiﬁed serological data from a
516 I. Rodriguez-Barraquer et al. / Va
Fig. 2. Effects of vaccination on the serotype speciﬁc incidence of dengue. Figure
showing example output of the “base case” simulation, where all serotypes are
equally transmissible, have an equal probability of leading to clinical disease and






































i.8. In panel B, vaccine efﬁcacy against DENV-2 was reduced to 0.05. Solid regions
ndicate cases occurring in unvaccinated population and hatched region indicates
hose occurring in people who have received at least one vaccine dose.
eroprevalence study conducted among school-children in Rayong
n 2010 [15,25].
.2. Simulated scenarios
Since a major objective of this study was to explore hetero-
eneities that could potentially lead to adverse results upon mass
accination (i.e. that could lead to increases in the number of cases),
e focused on scenarios that would favor the transmission of the
erotype with lowest vaccine efﬁcacy, i.e. DENV-2. Thus, the three
ain scenarios explored were: (a) risk of clinically apparent disease
fter infection by DENV-2 is greater than risk for other serotypes,
b) transmission intensity of DENV-2 is greater than transmission
ntensity of other serotypes, and (c) enhancement of infectiousness
pon secondary infection with DENV-2 is greater than enhance-
ent by other serotypes. Example output of the simulated annual
ncidence of clinically apparent dengue and seroprevalence under
he three scenarios explored is shown in the supplementary mate-
ial (Supplementary Figs. S2.2 and S2.3).
.3. Effects of partially effective vaccine on serotype distribution
Fig. 2 shows example output from simulations under the “base
ase”, where all serotypes are equally transmissible, have an equal
robability of leading to clinical disease, and do not interact. As
xpected, a vaccine that is equally effective against all serotypes
eads to a symmetric decline in the serotype speciﬁc incidence
Fig. 2A). In contrast, if the vaccine is only effective against 3 out of 4
irculating serotypes, reductions in the incidence of some serotypes
re accompanied by an absolute increase in the incidence from
erotypes with lower efﬁcacy (Fig. 2B). Since this model assumes
hat individuals can only suffer up to two infections, there is intrin-
ic competition between the dengue serotypes. Vaccine induced
eductions in the incidence of some serotypes reduces this compe-
ition and favors the serotype with lower vaccine efﬁcacy.
.4. Vaccine effects over a ten-year period
Fig. 3 summarizes the results obtained after performing simula-
ions over a wide range of vaccine efﬁcacies for the three scenarios.
n a large proportion of scenarios explored, partially effective vac-
ines result in a 50% or greater reduction in the cumulative number
f clinical cases over 10 years. This is the case even for scenarios that
ncluded large heterogeneities in the probability of infections beingccine 32 (2014) 514– 520
clinically apparent (Fig. 3A), transmission intensity (Fig. 3B) and
infectiousness enhancement (Fig. 3C). Decreases in the cumulative
number of cases were even more dramatic in simulations that con-
sidered low-transmission settings (see Supplementary materials
S3).
Our results also show that even in the presence of high efﬁ-
cacy against 3/4 serotypes (leading to near elimination of them,
Supplementary Fig. S2.5) vaccination can lead to non-signiﬁcant
reductions or even increases in the incidence of dengue under cer-
tain scenarios. Increases in the 10-year cumulative number of cases
were only observed for scenarios in which DENV-2 had a relative
risk of clinically apparent disease greater than two.
We  isolated the direct and indirect effects of vaccination at
the population level 10 years after vaccine introduction, by com-
paring the overall,  direct and indirect vaccine effects. While in the
vast majority of scenarios explored vaccination reduced the risk of
unvaccinated individuals by 50–80% (due to indirect effects), direct
effects of vaccination (i.e. reductions in the number of cases in
vaccinated individuals as compared to unvaccinated individuals)
were smaller (Fig. 4). Interestingly, in scenarios that included high
heterogeneity in the transmission intensity and very low vaccine
efﬁcacy against DENV-2, direct effects of vaccination were nega-
tive. However, even under these scenarios, there was  an absolute
reduction in the cumulative incidence among vaccinated indi-
viduals, as compared to themselves had no vaccination program
been implemented (counterfactual effect). This reduction reﬂects
the cumulative effects of both direct and indirect protection that
vaccinees experience.
3.5. Impact of vaccination on temporal dynamics and age of
infection
We  assessed the impact of vaccination on the yearly incidence
of clinically apparent dengue, across all serotypes, for 50 years
after vaccine introduction (Fig. 5). While signiﬁcant decreases were
observed in all scenarios (relative to the average incidence prior to
vaccination), several short-term increases over pre-vaccine levels
occur within thirty years of vaccine introduction. These increases
result from the build up of susceptible individuals in certain age
groups and, as expected, are less frequent in scenarios with higher
efﬁcacy against DENV-2. Despite these periodic increases, the
expected cumulative incidence of clinically apparent dengue was
signiﬁcantly lower than the cumulative incidence without vaccine
for the great majority of scenarios explored (Fig. 5, right panel).
We  also explored the impact of vaccination on the mean-age of
clinical cases (Fig. 6). While vaccination with high efﬁcacy across
all serotypes led to an increase in the mean age of cases, in cer-
tain instances of low vaccine efﬁcacy against DENV-2 we observed
decreases in the mean-age. The largest decreases were observed
in scenarios that included heterogeneity in transmission intensity
(Fig. 6B), and result mostly from breakthrough infections by DENV-
2 in vaccinated children. Sudden increases in the mean-age of cases
were also observed at varying times after vaccine introduction and
result from susceptibility accumulating in certain age-classes.
4. Discussion
The impact of any particular vaccine formulation depends on at
least four separate effects: (1) direct protection of vaccinees against
infection and/or disease, (2) indirect protection of all members of
vaccinated communities, (3) an impact on serotype distribution,
and (4) the immunopathogenic effects of partial vaccine-induced
immunity. Our results from a four-serotype, age-speciﬁc compart-
mental dengue transmission model suggest that partially effective
I. Rodriguez-Barraquer et al. / Vaccine 32 (2014) 514– 520 517
Fig. 3. The expected 10-year impact of vaccination with a partially effective vaccine under different scenarios is summarized. Each grid cell represents the ratio of the
cumulative number of dengue cases 10 years after vaccine introduction, vs. the cumulative number of cases in the same 10 years, had the vaccine not been introduced. We
































aC)  enhancement/inhibition of transmission intensity of secondary infections by DE
ssumed the efﬁcacy of the vaccine against other circulating serotypes to be 0.8.
accines can have a signiﬁcant positive impact, on average, in
educing dengue transmission and disease.
We evaluated the potential impact of mass vaccination with
artially effective vaccines in the presence of certain serotype
eterogeneities. Results from our simulations suggest that vac-
ines effective against only 3 out of 4 circulating serotypes can
ead to reductions even in scenarios where the serotype with low
r zero efﬁcacy (in this case DENV-2) is more pathogenic, more
ransmissible or experiences greater infectiousness enhancement.
hese ﬁndings indicate that vaccines effective against only three
erotypes may  have positive impacts at the population level, even
nder some of the adverse scenarios that led to recommendations
o focus on the development of tetravalent dengue vaccines [26].
These results provide insight into the impact that competition
etween serotypes may  have on the overall efﬁcacy of partially
ffective vaccines and are consistent with previously published
ork [27]. Assuming that individuals can only undergo up to two
nfections, in hyperendemic settings (where 2 or more serotypes
irculate) partially effective vaccines can lead to a decrease in com-
etition and increased transmission of serotypes for which the
accine has low efﬁcacy. The overall reduction in the number of
linical cases will depend on the pathogenicity of the serotypes
hat beneﬁt from this reduced competition.
Our results also show that vaccination might lead to a shift in the
ean-age of cases toward younger age groups. If vaccine induced
mmunity enhances severity of infections among those that experi-
nce infection, vaccinating young immunologically naive children
ight predispose them to clinically apparent disease earlier in life.
his result might have important implications since severe dengue
anifestations (dengue hemorrhagic fever and dengue shock syn-
rome) are thought to be more frequent and severe among infants
nd young children [28].
Finally, our results indicate that direct and indirect effects of
 vaccine could differ, potentially resulting in non-vaccinees in a(after prior primary exposure by any of the other serotypes). For all simulations we
highly vaccinated population experiencing the greatest reductions
in cumulative incidence of clinically apparent dengue. Much of
this effect is dictated by the immunopathogenic effects of vaccine
derived immunity that we  assumed, and would not be observed
if vaccine immunity conferred protection against clinical disease.
While in all of these instances the cumulative incidence in vaccinees
was  lower than what it would have been in the absence of vaccine,
and the overall population effects were positive, this ﬁnding raises
issues about the relevance of individual versus population protec-
tion. The use of incentives to promote vaccination may be used to
manage expectation regarding speciﬁc beneﬁts of vaccination vs.
non-vaccination under different vaccination coverages [29,30].
Two other efforts have recently estimated the potential impact
of a dengue vaccine [21,22]. Neither of these papers addresses the
potential impact of vaccines that differ in their efﬁcacy by serotype,
a key feature of the vaccine reported by Sabchaereon et al. [1]. A dif-
ference between our model and those by Chao et al. and Coudeville
is that ours assumes that people can only undergo natural infec-
tion by up to two  dengue serotypes while they assume that up to
four infections are possible. Our assumption is supported by the
low frequency of tertiary and quaternary infections among hospi-
tal cohorts [8,19] and by the broadly cross-reactive neutralizing
antibody response that is maintained after secondary infection.
However, whether tertiary and quaternary play some role in the
transmission dynamics of dengue is still under debate. Relaxing
this assumption would remove the competition between serotypes
imposed by our model, and in general lead to greater reductions in
cumulative incidence with the use of partially effective vaccines.
Our model makes the assumption that the probability of devel-
oping clinically apparent disease is higher in the presence of
pre-existing immunity, regardless of whether this immunity is the
result of natural infection or vaccination. A similar assumption is
made in the model by Coudeville [22]. While in the context of nat-
ural infections it is well established that pre-existing immunity
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Fig. 4. The expected 10-year vaccine effects of a partially effective vaccine under different scenarios is summarized. We performed simulations over a wide range of
vaccine  efﬁcacies (for DENV-2) and sources of heterogeneity in (A) relative risk of DENV-2 being clinically apparent, (B) relative transmission intensity of DENV-2, and (C)
enhancement/inhibition of transmission intensity of secondary infections by DENV-2 (after prior primary exposure to any of the other serotypes). See Section 2 for description
of  effects. Each grid cell represents the 10-year population vaccine effect for that particular scenario. For all simulations we assumed the efﬁcacy of the vaccine against other


















dgainst a heterologous serotype is the main risk-factor for the
evelopment of severe disease [7], immunopathogenic effects of
accine-induced immunity are yet to be elucidated. If heterologous
accine induced immunity protects against infection or clinically
pparent disease, the impact of partially effective vaccines will be
reater than that estimated by our model.
While we calibrated our transmission parameters to ﬁt the
ge distribution of seroprevalence and reported cases in Rayong,
hailand, current knowledge of dengue epidemiology can distin-
uish between many of the scenarios that we simulated. Multiple
tudies have found evidence of heterogeneity [14,31,32] but the
xtent to which heterogeneity in clinical expression, transmissibil-
ty or enhancement exists is not known. One of the main objectives
f this research was to identify scenarios that could potentially
esult in adverse population effects after mass vaccination with
artially effective vaccines, and therefore we deliberately chose to
xplore a wide parameter space, even if this resulted in unrealistic
ynamics in some cases.
There are important gaps in our understanding of serotype
ynamics, cross-protection [33], enhancement and pathogenicity[34–36]. Our results aim to represent hyperendemic areas gen-
erally, but predicting the potential impact of vaccination in any
speciﬁc setting would require extensive serotype-speciﬁc longi-
tudinal data that is only available from cohort studies. While our
sensitivity analyses suggest that partially effective vaccines have
the potential to be even more useful in settings with stable low
transmission, better understanding of the changing epidemiology
of dengue in settings of more recent re-emergence (e.g., South
America and the Indian sub-continent) will be fundamental to
properly model the impact of vaccines in these settings.
Dengue vaccine development efforts have been ongoing for
several decades and have focused on the development of tetrava-
lent vaccines. The realities of vaccine development and individual
heterogeneity in vaccine responses indicate that vaccines might
not invoke a strong protective response in all individuals to
all serotypes. Our results suggest that despite the virologic and
immunologic characteristics of dengue, partially effective vaccines
have the potential to be important tools for dengue control. Con-
sideration of imperfect vaccines will require careful measurement
of the epidemiology of dengue in each place that vaccine might
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Fig. 5. Incidence of clinical dengue over time after vaccine introduction. Figure showing changes in the incidence of clinical dengue during the years following vaccine
introduction (time = 0, dashed line). Left: relative yearly incidence of clinical dengue as compared to the average yearly incidence before vaccine introduction. Right: reductions
in  the cumulative incidence of clinical dengue at different times after vaccine introduction, relative to the cumulative incidence had the vaccine not been introduced. We
present results for three different scenarios. (A) Risk of developing clinical disease after DENV-2 infection is 1.5 times greater than after infection by any other serotype.
(B)  Transmission intensity of DENV-2 is 1.5 times higher than the transmission intensity of any other serotype. (C) Secondary infection by DENV-2 results in infectiousness
enhancement by a factor of 1.5. In all cases, the vaccine efﬁcacy against dengue 1, 3, and 4 was assumed to be 0.8.
Fig. 6. Age distribution of clinical cases over time after vaccine introduction. Left panels show changes in the mean age of dengue cases during the years following vaccine
introduction (dashed line) as compared to the years before vaccine introduction. Right panels show changes in the age distribution of clinical cases for the three time points
marked  with open circles in the corresponding left panel. We  present results for three different scenarios. (A) Risk of developing clinical disease after DENV-2 infection is 1.5
times  greater than after infection by any other serotype. (B) Transmission intensity of DENV-2 is 1.5 times higher than the transmission intensity of any other serotype. (C)
Secondary infection by DENV-2 results in infectiousness enhancement by a factor of 1.5. In all cases, the vaccine efﬁcacy against dengue 1, 3, and 4 was assumed to be 0.8.
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